Asset
NAPAZIMONE
PHARMING GROUP N.V. ADS EACH REPRESENTING 10 ORDINARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05650229 | phase2 | recruiting | 2022-12-13 | 2027-10-01 | Pharming Technologies B.V. | Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease |
| NCT07514338 | phase2 | recruiting | 2026-06-12 | 2029-03-31 | Pharming Technologies B.V. | Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease |
FDA applications (0)
This company has no applications containing this asset.